NCT00549848View on ClinicalTrials.gov

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 29, 2007

Primary Completion Date

September 26, 2020

Study Completion Date

March 26, 2022

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine

See Detailed Description section for details of treatment interventions.

DRUG

Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib

See Detailed Description section for details of treatment interventions.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Enzon Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

St. Jude Children's Research Hospital

OTHER